ANI Pharmaceuticals (FRA:BSFA) Margin of Safety % (DCF FCF Based): N/A (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BSFA ANI Pharmaceuticals Inc FRA:BSFA
78 GF Score
Price €66.00
GF Value €85.45
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ANI Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

ANI Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

FRA:BSFA vs TRLV, AMLX, XERS: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ANI Pharmaceuticals Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.


FRA:BSFA
78GF Score
ANI Pharmaceuticals Inc FRA:BSFA
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ANI Pharmaceuticals (FRA:BSFA) Overvalued in 2026?

Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued. The current stock price of €66.00 is trading 22.8% below its estimated GF Value™ of €85.45. GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for FRA:BSFA:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €85.45 vs. price of €66.00 (22.8% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the FRA:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ANI Pharmaceuticals Business Description

Other Exchanges ANIP:USA
Address 210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
78GF Score

Get the complete analysis for FRA:BSFA

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.00
Price
€85.45
GF Value